November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
INAVO120: Inavolisib with Palbociclib–Fulvestrant Doubles PFS in PIK3CA-Mutated Breast Cancer
Nov 2, 2024, 02:08

INAVO120: Inavolisib with Palbociclib–Fulvestrant Doubles PFS in PIK3CA-Mutated Breast Cancer

Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared a post by NEJM , on X:

INAVO120 published in NEJM

In 1st-line treatment, inavolisib + palbociclib–fulvestrant improved PFS (15.0 vs. 7.3 months; HR 0.43, P<0.001) in PIK3CA-mutated, ER+/HER2- metastatic breast cancer vs. placebo Response rate: 58.4% vs. 25.0%.

Quoting NEJM‘s post:

INAVO120 trial: In PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib–fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib–fulvestrant.

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Authors: Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid,  Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman,  Chunyan Song, and Komal L. Jhaveri.

INAVO120: Inavolisib with Palbociclib–Fulvestrant Doubles PFS in PIK3CA-Mutated Breast Cancer